The complement system as a therapeutic target in autoimmunity.
about
Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayersDesign and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseasesGene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis.Circulating immune complexes and complement C3 and C4 levels in a selected group of patients with rhinitis in LebanonComplement regulation: physiology and disease relevanceDiscovery, linkage disequilibrium and association analyses of polymorphisms of the immune complement inhibitor, decay-accelerating factor gene (DAF/CD55) in type 1 diabetesAge-related macular degeneration--emerging pathogenetic and therapeutic concepts.Complement factor H: using atomic resolution structure to illuminate disease mechanisms.Blockade of autoantibody-initiated tissue damage by using recombinant fab antibody fragments against pathogenic autoantigenLinking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosusA polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaFragment Bb: evidence for activation of the alternative pathway of the complement system in pregnant women with acute pyelonephritis.Complement and viral pathogenesisMannose binding lectin is required for alphavirus-induced arthritis/myositis.B cells as a therapeutic target in autoimmune diseases.B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis.Complement in Action: An Analysis of Patent Trends from 1976 Through 2011.Alternative complement pathway activation fragment Bb in early pregnancy as a predictor of preeclampsia.Therapeutic inhibition of the alternative complement pathway attenuates chronic EAE.Activation of the alternative pathway of complement is a feature of pre-term parturition but not of spontaneous labor at termFragment Bb in amniotic fluid: evidence for complement activation by the alternative pathway in women with intra-amniotic infection/inflammationAntigen-specific immunotherapy for autoimmune diseases.Stabilizing endothelium of donor hearts with fusogenic liposomes reduces myocardial injury and dysfunctionIdentification of candidate genes for human retinal degeneration loci using differentially expressed genes from mouse photoreceptor dystrophy modelsComplement activation fragment Bb in early pregnancy and spontaneous preterm birthMolecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor.Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin.The Relationship of Longitudinal Levels of Complement Bb During Pregnancy with Preeclampsia.B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35).Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.Modulators of complement activation: a patent review (2008 - 2013).Complement and autoimmunity.Correlation between clinical and histologic findings in the human neonatal hippocampus after perinatal asphyxia.
P2860
Q24598616-6CB3A0C8-5C25-4007-8441-D96F87315777Q24632001-6183FB81-CFCD-495A-A048-BB4AD8EBA431Q24799004-BB45D1F2-D3F7-41D9-8AA1-6A76EAB3CB7CQ24800358-A9473733-77E3-4F1F-BF1F-DB9E4AE90934Q26795441-EFC07D4A-842F-47F6-B277-EF14846A122DQ33240464-DA986C9B-8AC3-4E23-8F2B-B58084E1BC2AQ33263472-ED19F011-1FD3-4289-BE60-4D14A27EAC00Q33382097-EC191AD7-8995-4771-8F22-1B1817ADEDB2Q33521430-7C556581-735B-4B41-8005-5DC430DFE02EQ33599086-5A49D412-A77B-4F02-8F12-8FDB98E93E31Q34007430-ECA0D854-AF9A-4D21-95D1-384D6AC84884Q34139940-76606FF0-C3A8-40DC-AD79-BE1470889C5AQ34162421-49739F2F-7903-418C-B9B1-B2D0199A5ABFQ34211498-440534CC-BFEA-4B8B-AD2D-6C657F9E7258Q36158684-237D4089-06BB-42CE-B3AE-CAE762A28E09Q36328407-7F3BCA3E-A858-4A5C-8310-19FC96614848Q36503765-65060451-138A-4BA0-9E91-AC4501E320AEQ36618406-9D68C9EE-E69B-41FD-9E13-7F5747D8AF62Q36698228-EA19C399-627B-4360-8C40-CB314BD9D367Q36714154-EAD84664-95C6-4BB6-BAC8-62D307E4FD3BQ36720470-44C30D7F-3CD7-43C2-8E4F-1AC9AB97E2F2Q36739772-E8E00990-E7A8-4A49-A1C8-5BC8920F611FQ36746563-D454326B-245D-4AAB-A382-3F8828504490Q36862958-D996E093-E9A7-4230-A2D1-5314A72CC7A7Q36980611-12920852-7035-4F36-87FC-77773A844192Q37133741-730010FD-DD0D-4887-BFFD-FF65DD629110Q37272142-500704A4-E7B3-4B81-A27B-338046EEAE44Q37384384-9267C581-78F8-4BF4-A083-F282FA7AB52FQ37486139-345FE3F5-2704-4C63-A16D-9E0924DB421CQ37586921-EED4CC06-0B7C-4A3F-B3CA-7C4A7CB06A84Q37623820-FD4996B4-10CE-4AF6-97FF-781EEE779B91Q37716557-D0C5DA6C-8DDC-490D-BF94-EDCC333145FCQ38196860-F7C2E2C9-BA60-4AE6-B486-F50B252BF8EBQ45169996-D66594CB-BFC3-4CDF-A79D-B05970087279Q46482414-77238A0C-6120-41D3-813C-570545E3C425
P2860
The complement system as a therapeutic target in autoimmunity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The complement system as a therapeutic target in autoimmunity.
@ast
The complement system as a therapeutic target in autoimmunity.
@en
type
label
The complement system as a therapeutic target in autoimmunity.
@ast
The complement system as a therapeutic target in autoimmunity.
@en
prefLabel
The complement system as a therapeutic target in autoimmunity.
@ast
The complement system as a therapeutic target in autoimmunity.
@en
P1433
P1476
The complement system as a therapeutic target in autoimmunity.
@en
P2093
V Michael Holers
P304
P356
10.1016/S1521-6616(03)00034-2
P577
2003-06-01T00:00:00Z